Heart rate in ischemic heart disease. The innovation of ivabradine: More than pure heart rate reduction

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

A wealth of data suggests that heart rate (HR) is an independent predictor of cardiovascular and all-cause mortality in men and women of all ages with and without cardiovascular disease. Data gathered from clinical trials suggest that HR reduction is an important mechanism of benefit of HR-lowering drugs. A high HR has direct detrimental effects not only on myocardial ischemia but also on the progression of atherosclerosis, ventricular arrhythmias, and on left ventricular function. The risk increases with HR >60 b.p.m. Ivabradine, a drug that slows HR though an effect on the If channels, has been approved for the control of myocardial ischemia in patients with coronary artery disease intolerant to beta-blockers. More recently, the indication of ivabradine has been extended for use in association with beta-blockers in patients with coronary artery disease. The effects of ivabradine on myocardial ischemia are greater than those predicted by pure HR reduction with beta-blockers, suggesting additional mechanisms of action.

Original languageEnglish
Pages (from-to)202-210
Number of pages9
JournalAdvances in Therapy
Volume27
Issue number4
DOIs
Publication statusPublished - Apr 2010

Fingerprint

ivabradine
Myocardial Ischemia
Heart Rate
Coronary Artery Disease
Left Ventricular Function
Pharmaceutical Preparations
Cardiac Arrhythmias
Atherosclerosis
Cardiovascular Diseases

Keywords

  • Acute myocardial infarction
  • Coronary artery disease
  • Heart rate
  • Myocardial ischemia

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Medicine(all)

Cite this

@article{e1d45c3069044555812beef125255774,
title = "Heart rate in ischemic heart disease. The innovation of ivabradine: More than pure heart rate reduction",
abstract = "A wealth of data suggests that heart rate (HR) is an independent predictor of cardiovascular and all-cause mortality in men and women of all ages with and without cardiovascular disease. Data gathered from clinical trials suggest that HR reduction is an important mechanism of benefit of HR-lowering drugs. A high HR has direct detrimental effects not only on myocardial ischemia but also on the progression of atherosclerosis, ventricular arrhythmias, and on left ventricular function. The risk increases with HR >60 b.p.m. Ivabradine, a drug that slows HR though an effect on the If channels, has been approved for the control of myocardial ischemia in patients with coronary artery disease intolerant to beta-blockers. More recently, the indication of ivabradine has been extended for use in association with beta-blockers in patients with coronary artery disease. The effects of ivabradine on myocardial ischemia are greater than those predicted by pure HR reduction with beta-blockers, suggesting additional mechanisms of action.",
keywords = "Acute myocardial infarction, Coronary artery disease, Heart rate, Myocardial ischemia",
author = "Rosano, {Giuseppe M C} and Cristiana Vitale and Maurizio Volterrani",
year = "2010",
month = "4",
doi = "10.1007/s12325-010-0030-9",
language = "English",
volume = "27",
pages = "202--210",
journal = "Advances in Therapy",
issn = "0741-238X",
publisher = "Springer Healthcare",
number = "4",

}

TY - JOUR

T1 - Heart rate in ischemic heart disease. The innovation of ivabradine

T2 - More than pure heart rate reduction

AU - Rosano, Giuseppe M C

AU - Vitale, Cristiana

AU - Volterrani, Maurizio

PY - 2010/4

Y1 - 2010/4

N2 - A wealth of data suggests that heart rate (HR) is an independent predictor of cardiovascular and all-cause mortality in men and women of all ages with and without cardiovascular disease. Data gathered from clinical trials suggest that HR reduction is an important mechanism of benefit of HR-lowering drugs. A high HR has direct detrimental effects not only on myocardial ischemia but also on the progression of atherosclerosis, ventricular arrhythmias, and on left ventricular function. The risk increases with HR >60 b.p.m. Ivabradine, a drug that slows HR though an effect on the If channels, has been approved for the control of myocardial ischemia in patients with coronary artery disease intolerant to beta-blockers. More recently, the indication of ivabradine has been extended for use in association with beta-blockers in patients with coronary artery disease. The effects of ivabradine on myocardial ischemia are greater than those predicted by pure HR reduction with beta-blockers, suggesting additional mechanisms of action.

AB - A wealth of data suggests that heart rate (HR) is an independent predictor of cardiovascular and all-cause mortality in men and women of all ages with and without cardiovascular disease. Data gathered from clinical trials suggest that HR reduction is an important mechanism of benefit of HR-lowering drugs. A high HR has direct detrimental effects not only on myocardial ischemia but also on the progression of atherosclerosis, ventricular arrhythmias, and on left ventricular function. The risk increases with HR >60 b.p.m. Ivabradine, a drug that slows HR though an effect on the If channels, has been approved for the control of myocardial ischemia in patients with coronary artery disease intolerant to beta-blockers. More recently, the indication of ivabradine has been extended for use in association with beta-blockers in patients with coronary artery disease. The effects of ivabradine on myocardial ischemia are greater than those predicted by pure HR reduction with beta-blockers, suggesting additional mechanisms of action.

KW - Acute myocardial infarction

KW - Coronary artery disease

KW - Heart rate

KW - Myocardial ischemia

UR - http://www.scopus.com/inward/record.url?scp=77953021351&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953021351&partnerID=8YFLogxK

U2 - 10.1007/s12325-010-0030-9

DO - 10.1007/s12325-010-0030-9

M3 - Article

C2 - 20495895

AN - SCOPUS:77953021351

VL - 27

SP - 202

EP - 210

JO - Advances in Therapy

JF - Advances in Therapy

SN - 0741-238X

IS - 4

ER -